Woodline Partners’s Prelude Therapeutics PRLD Stock Holding History

Woodline Partners’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200,000	Closed	-$618K	–	617
2023 Q3	$618K	Sell	200,000 -48,000	-19%	-$180K	0.01%	482
2023 Q2	$1.12M	Buy	+248,000	New	+$1.48M	0.01%	474
2020 Q4	–	Sell	-179,361	Closed	-$5.4M	–	261
2020 Q3	$5.4M	Buy	+179,361	New	+$5.07M	0.18%	122

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's PRLD Position: Q4 2023 in Review

Woodline Partners sold out of Prelude Therapeutics (PRLD) in Q4 2023, closing a stake of 200,000 shares — an estimated $618K sold.

Woodline Partners first reported a position in PRLD in Q3 2020 and held it in 3 quarters. The position peaked at $5.4M in Q3 2020. 56 funds tracked by Wall St. Rank hold PRLD as of Q4 2023.

Woodline Partners reported no remaining Prelude Therapeutics position as of Q4 2023 after selling out during the quarter.
Woodline Partners sold 200,000 Prelude Therapeutics shares in Q4 2023, an estimated $618K.
Woodline Partners first reported a position in Prelude Therapeutics in Q3 2020 and held it in 3 quarters.
Woodline Partners's Prelude Therapeutics position peaked at $5.4M in Q3 2020.
56 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2023.

Based on Woodline Partners's 13F filing for Q4 2023, filed 14 Feb 2024.